14 completed, 5 recruiting, 3 unknown, 2 withdrawn. 25 Phase 2, 4 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Completed 14, Recruiting 5, Unknown 3, Withdrawn 2, Not yet recruiting 1 |
| Phase 1 | 4 | Completed 2, Not yet recruiting 1, Recruiting 1 |
| Phase 3 | 2 | Recruiting 2 |
Follow Tremor: new trials by email Literature Review of Tremor trials Research Report on Tremor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus) Glycerol Tributyrate - MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus) | Phase 1 / Phase 2 | Not yet recruiting | George Washington University | 24 | 2027-03-01 | 2026-10-05 |
| A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy VIM0423, VIM0423 Placebo - PARKINSON DISEASE (Disorder) | Phase 2 | Recruiting | Vima Therapeutics | 80 | 2026-09-15 | 2026-11-10 |
| Virtual tES Device Treatment for Parkinson's Disease Motor Symptoms Transcranial Electrical Stimulation Device - PARKINSON DISEASE (Disorder) | Phase 1 / Phase 2 | Recruiting | U: The Mind Company | 30 | 2026-01-01 | 2026-01-27 |
| Stereotactic Radiosurgery in the Treatment of Essential Tremor Stereotactic Radiosurgery - Essential Tremor | Phase 2 | Recruiting | Maria Sklodowska-Curie National Research Institute of Oncology | 42 | 2024-12-16 | 2026-10-20 |
| A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease Placebo, Suvecaltamide - Parkinson Disease, Tremor | Phase 2 | Completed | Jazz Pharmaceuticals | 169 | 2022-12-01 | 2026-01-15 |
| A Clinical Trial of PRAX-114 in Participants With Essential Tremor 10 mg PRAX-114, 20 mg PRAX-114, and Placebo, 10 mg PRAX-114 or 20 mg PRAX-114 - Essential Tremor | Phase 2 | Withdrawn | Praxis Precision Medicines | 2022-04-05 | 2022-11-30 | |
| A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET) JZP385, Placebo - Essential Tremor | Phase 2 | Completed | Jazz Pharmaceuticals | 420 | 2021-12-06 | 2025-07-24 |
| Bilateral Essential Tremor Treatment With Gamma Knife Gamma Knife VIM thalamotomy - Essential Tremor | Phase 2 / Phase 3 | Recruiting | Université de Sherbrooke | 50 | 2021-06-08 | 2021-11-17 |
| A Phase 2 Study of CX-8998 in Adults With Tremor Associated With Parkinson's Disease CX-8998, Placebo - Parkinson's Disease, Tremor | Phase 2 | Withdrawn | Jazz Pharmaceuticals | 2019-12-01 | 2021-05-28 | |
| CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients Envarsus XR - Kidney Pancreas Transplantation | Phase 2 / Phase 3 | Recruiting | University of Wisconsin, Madison | 20 | 2019-02-27 | 2026-10-29 |
| A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease Cannabidiol, Placebo - Parkinson Disease | Phase 2 | Completed | University of Colorado, Denver | 74 | 2018-09-05 | 2024-07-23 |
| Effectiveness of Botox on Reducing Rest Tremor in Parkinson's Disease Onabotulinumtoxin A Injection, Placebo - Parkinson Disease | Phase 2 | Completed | University of North Carolina, Chapel Hill | 16 | 2018-03-22 | 2020-08-17 |
| A Study to Evaluate SAGE-217 in Participants With Essential Tremor SAGE-217, Placebo - Essential Tremor | Phase 2 | Completed | Biogen | 34 | 2017-03-24 | 2023-11-28 |
| A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease cannabidiol - Parkinson's Disease | Phase 2 | Completed | University of Colorado, Denver | 13 | 2016-10-01 | 2019-02-19 |
| Kinematic-based BoNT-A Bilateral Upper Limb PD Therapy Botulinum Toxin Type A - Parkinson's Disease | Phase 2 | Unknown | Western University, Canada | 50 | 2016-03-01 | 2020-03-11 |
| An Effectiveness and Toxicity of CyberKnife Based Radiosurgery for Parkinson Disease Radiosurgical thalamotomy, CyberKnife - Parkinson Disease | Phase 2 | Unknown | Maria Sklodowska-Curie National Research Institute of Oncology | 27 | 2015-01-01 | 2015-04-02 |
| Effects of Octanoic Acid for Treatment of Essential Voice Tremor Octanoic acid, Inactive capsule - Essential Voice Tremor, Vocal Tremor | Phase 1 / Phase 2 | Completed | Syracuse University | 17 | 2013-07-01 | 2018-08-20 |
| Randomised Crossover Trial of DBS of Differential PSA Regions in Parkinson's Disease and Tremor Up to 3 mA, 60 us, 130 Hz deep brain stimulation, Empirical unblinded deep brain stimulation programming - Parkinson's Disease, Tremor | Phase 2 | Completed | The University of Western Australia | 39 | 2012-08-01 | 2021-05-18 |
| Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized Approach incobotulinumtoxinA, Saline - Parkinson, Tremor | Phase 2 | Completed | Yale University | 33 | 2012-08-01 | 2016-03-14 |
| Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response Sodium oxybate - Spasmodic Dysphonia, Voice Tremor | Phase 2 | Completed | Kristina Simonyan | 53 | 2012-07-01 | 2017-11-22 |
Showing 20 of 25. Sign in to see all of them.
Essential Tremor (10) · Parkinson Disease (10) · Movement Disorders (7) · Dyskinesias (4) · Anxiety Disorders (3) · Central Nervous System Diseases (3) · Dysphonia (2) · Dystonia (2) · Marijuana Abuse (2) · Nervous System Diseases (2) · Psychotic Disorders (2) · Acidosis, Lactic (1) · Brain Diseases (1) · Cognition Disorders (1)
Pathological Conditions, Signs and Symptoms (25) · Signs and Symptoms (25) · Neurologic Manifestations (24) · Nervous System Diseases (23) · Dyskinesias (21) · Central Nervous System Diseases (17) · Movement Disorders (12) · Basal Ganglia Diseases (10) · Brain Diseases (10) · Synucleinopathies (10) · Neurodegenerative Diseases (9) · Parkinsonian Disorders (9) · Mental Disorders (3) · Otorhinolaryngologic Diseases (3) · Chemically-Induced Disorders (2)
Botulinum Toxins, Type A (3) · incobotulinumtoxinA (3) · Cannabidiol (2) · Radiosurgery (2) · Ethanol (1) · Levetiracetam (1) · S-2-O-carbamoyl-1-o-chlorophenyl-ethanol (1) · Saline Solution (1) · Sodium Chloride (1) · Sodium Oxybate (1) · Tacrolimus (1) · octanoic acid (1) · zuranolone (1)
Jazz Pharmaceuticals (3) · Maria Sklodowska-Curie National Research Institute of Oncology (2) · University of Colorado, Denver (2) · Western University, Canada (2) · Biogen (1) · George Washington University (1) · Kristina Simonyan (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · Praxis Precision Medicines (1) · SK Life Science, Inc. (1) · Sonexa Therapeutics, Inc. (1) · Southern California Institute for Research and Education (1) · Syracuse University (1) · The University of Western Australia (1) · U: The Mind Company (1)
United States (17) · Poland (4) · Canada (3) · Germany (2) · Spain (2) · Australia (1)
Aleksandra Napieralska (1) · Anne Chiaramello, Ph.D. (1) · Bahman Jabbari, MD (1) · Christopher Lind, MBChB, FRACS (1) · Daniel A Roque, MD (1) · Debra Regier, M.D., Ph.D. (1) · Jon S Odorico, MD (1) · Kristina Simonyan, MD, PhD (1) · Leszek Miszczyk, MD, PhD (1) · Mandar Jog, MD (1) · Mandar Jog, MD, FRCPC (1) · Maureen A Leehey, M.D. (1) · Maureen Leehey (1)
PMID 14718713, PMID 15210907, PMID 20201005, PMID 21594724, PMID 22454323, PMID 23408867, PMID 25929664, PMID 27101283, PMID 27808415, PMID 28789780, PMID 30382161, PMID 37448353, PMID 38466972
R01DC012545 (1), R03DC012429 (1), UH3TR003897 (1)